Makers of generics should develop abuse-resistant oxycodone

04/22/2013 | New York Times (tiered subscription model), The

Makers of generic drugs should market their own abuse-resistant formulations of the painkiller OxyContin, or oxycodone, following an FDA ruling that will block the entry of generic versions of the original formulation from the market, according to this editorial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX